Origins, Development, Current Challenges and Future Directions with Activated Prothrombin Complex Concentrate for the Treatment of Patients with Congenital Haemophilia with Inhibitors

Hans H. Brackmann1 Wolfgang Schramm2 Johannes Oldenburg1 Viridiana Cano3 Peter L. Turecek4 Claude Négrier5

1 Haemophilia Center, Institute of Experimental Haematology and Blood Transfusion, University of Bonn, Bonn, Germany
2 Rudolf Marx-Stiftung für Hämostaseologie, Universität München and Bluterbetreuung Bayern e. V. (BBB) - Germany
3 Shire International GmbH, a Takeda company, Zürich, Switzerland
4 Baxalta Innovations GmbH, a Takeda company, Vienna, Austria
5 Haemophilia and Thrombosis Centre, Louis Pradel Hospital, University Claude Bernard Lyon 1, Lyon, France

Address for correspondence Peter L. Turecek, PhD, Baxalta Innovations GmbH, a Takeda company, DC-Tower, Donau-City-Straße 7, A-1220 Vienna, Austria (e-mail: peter.turecek@takeda.com).

Hämostaseologie 2020;40:606–620.

Abstract

Congenital haemophilia A (HA) is caused by deficiency of coagulation factor VIII (FVIII) activity, leading to spontaneous or traumatic bleeding events. While FVIII replacement therapy can treat and prevent bleeds, approximately 30% of patients with severe HA develop inhibitor antibodies that render FVIII replacement therapy ineffective. The bypassing agents (BPAs), activated prothrombin complex concentrate (aPCC) and recombinant activated FVII, first approved in 1977 and 1996, respectively, act to generate thrombin independent of pathways that involve factors IX and VIII. Both may be used in patients with congenital haemophilia and inhibitors (PwHI) for the treatment and prevention of acute bleeds and quickly became standard of care. However, individual patients respond differently to different agents. While both agents are approved for on-demand treatment and perioperative management for patients with congenital haemophilia with inhibitors, aPCC is currently the only BPA approved worldwide for prophylaxis in PwHI. Non-factor therapies (NFTs) have a mechanism of action distinct from BPAs and have reported higher efficacy rates as prophylactic regimens. Nonetheless, treatment challenges remain with NFTs, particularly regarding the potential for synergistic action on thrombin generation with concomitant use of other haemostatic agents, such as BPAs, for the treatment of breakthrough bleeds and in perioperative management. Concomitant use of NFTs with other haemostatic agents could increase the risk of adverse events such as thromboembolic events or thrombotic microangiopathy. This review focuses on the origins, development and on-going role of aPCC in the evolving treatment landscape in the management of PwHI.

Keywords

► congenital haemophilia
► inhibitors
► bypassing agents
► FEIBA
► aPCC

received February 12, 2020 accepted after revision April 16, 2020

DOI https://doi.org/10.1055/a-1159-4273.
ISSN 0720-9355.

© 2020 Georg Thieme Verlag KG Stuttgart · New York
License terms
Introduction

Congenital haemophilia A (HA) and B (HB) are bleeding disorders characterised by a deficiency of blood clotting factor VIII (FVIII) or factor IX (FIX), respectively. The type of FVIII/IX mutation present is a major determinant of severity and bleeding tendency. Severe cases present with bleeding and joint bleeds from early childhood, which, without appropriate treatment and prevention, can result in irreversible joint damage and chronic arthropathy.

Strides have been made in the management of congenital haemophilia over recent decades, including the introduction of plasma-derived and recombinant clotting factor products, use of prophylaxis as standard of care for bleeding prevention, and appropriate surgical management. Such therapy has led to improvements in the health of patients with haemophilia by suppressing the onset of joint damage and arthropathy, preventing life-threatening bleeds, and improving patient quality of life. Nevertheless, treatment challenges remain. First, for patients receiving FVIII/IX products, intravenous infusion is required up to every 2 days for patients with severe HA and at least twice weekly for those with severe HB. Although high infusion frequency can be reduced with the use of extended half-life products, the frequency can still be burdensome. Second, treatment can be complicated by the development of alloantibodies (inhibitors) that bind to FVIII or FIX, preventing its haemostatic action. Such antibodies can neutralise therapeutically administered factor replacement products, and occur in up to 25 to 40% of severe HA patients, 5 to 15% of moderate/mild HA patients and 1 to 5% of patients with severe HB. Anaphylactic reactions and nephrotic syndrome are also not uncommon in patients with HB and inhibitors.

The aetiology of inhibitor development is multifactorial, including both genetic and treatment-related risk factors. Presence of inhibitors is associated with reduced treatment efficacy, increased occurrence of life-threatening bleeds and severe joint damage, which can lead to poor quality of life for patients, family and caregivers; higher morbidity and mortality rates; and increased healthcare costs. Recommended treatment of patients with congenital haemophilia and inhibitors (PwHIs) has focused on eradicating inhibitors using immune tolerance induction (ITI) therapy. ITI regimens vary and can be used with or without bypassing agents (BPAs) for the treatment of breakthrough bleeding, surgical setting and prophylaxis.

BPAs were developed to ‘bypass’ the factors blocked by inhibitors, and function by generating thrombin via pathways that do not require activation of FVIII or FIX. Two BPAs are currently available: activated prothrombin complex concentrate (aPCC, FEIBA [factor eight inhibitor bypass activity]; Takeda, Lexington, Massachusetts, United States) and recombinant activated FVII (rFVIIa, NovoSeven; NovoNordisk, Bagsvaerd, Denmark). Both compounds have been approved for on-demand treatment and perioperative management for PwHIs, while aPCC is the only compound approved worldwide for prophylaxis in PwHI.

Both aPCC and rFVIIa have efficacy rates >80% in the control of acute bleeding events, with comparable tolerability and low rate of thrombotic complications, as concluded by a Cochrane systematic review. The choice of BPA for on-demand treatment may be driven by several factors, including burden of the infusion due to volume and infusion time, experience of treat er and/or patient preference. Furthermore, individuals may show a better response to one agent over another, as reflected in the FEIBA NovoSeven Comparative (FENOC) study, in which 32% of patients reported efficacy for either aPCC or rFVIIa at 6 hours post-treatment. Achievement of good haemostatic efficacy within the first few hours of a bleed can reduce the risk of cartilage destruction; therefore, selection of the most appropriate BPA for each individual is important.

Treatments with different mechanisms of action that aim to address the challenges of treating PwHI are in development. Here, we review the role of aPCC in an evolving treatment landscape for patients with congenital HA with inhibitors.

Development of Activated Prothrombin Complex Concentrate

The clinical use of prothrombin complex concentrates (PCCs) was extended early beyond their basic use as a substitution therapy for patients with prothrombin complex protein deficiencies, particularly for those with a FIX deficiency (HB), to the treatment of those with inhibitory antibodies against FVIII and FIX. However, the clinical use of PCCs remained a niche indication for many years. Only six treatment episodes were reported until 1977. For a long time, the clinical success of PCCs in the management of patients with inhibitors was attributed to the activated prothrombin complex enzyme in addition to the zymogen content of the concentrates. Therefore, in the early 1970s, the so-called auto-FIX concentrates were developed as a new therapeutic approach for treating HA patients with inhibitors. The independent development of commercial PCCs began around 1970 by two laboratories in parallel: Hyland Laboratories in the United States developing anti-inhibitor coagulant complex (Autoplex) and Immuno AG in Austria developing aPCC (FEIBA), the latter of which became the mainstay of treatment for patients with inhibitors.

aPCC is a plasma-derived, vapour-heated and nano-filtered (35 nM) concentrate of primarily vitamin K-dependent clotting factors (FII, FVII, FIX and FX) in both their zymogen and active forms (Table 1) that is proposed to act at cellular surfaces near the site of injury. It has been commercially available since 1977 to bypass the need for FVIII and FIX and to control and prevent bleeding in PwHIs. It is approved in over 80 countries and is indicated for control of spontaneous bleeds, perioperative management and routine prophylaxis for patients with congenital HA or HB with inhibitors and for the treatment of spontaneous bleeds and perioperative management for patients with acquired HA. Please note that indications do vary by country.

The mechanism of action of aPCC is multi-site and involves three main steps (Fig. 1). First, FII–FXa complex triggers immediate thrombin generation (TG) on the
Table 1 Haemostatic components of aPCC

| Component                  | Units per 1 U of FEIBA<sup>a</sup> |
|----------------------------|-----------------------------------|
| Prothrombin (factor II)    | 1.3 ± 0.3                         |
| Thrombin                   | 0.01 ± 0.004                      |
| Factor VII                 | 0.9 ± 0.1                         |
| Factor VIIa                | 1.5 ± 0.2                         |
| Factor IX                  | 1.4 ± 0.1                         |
| Factor IXa                 | approx. 0.0006                    |
| Factor X                   | 1.1 ± 0.2                         |
| Factor Xa                  | 0.06 ± 0.002                      |
| Factor VIII                | 0.03–0.1                          |
| Factor V                   | approx. 0.6                       |
| Protein C                  | 1.1 ± 0.2                         |
| Protein S                  | approx. 0.4                       |

Note: Activated prothrombin complex concentrate (aPCC) composition based on data obtained during the release procedure of aPCC and measured in the research laboratories at Baxter as described in the methods. 41,58

*aOne unit of factor eight inhibitor bypass activity (FEIBA) is defined as the amount of FEIBA capable of shortening the clotting time of high-titre FVIII inhibitor plasma by 50%.

membrane surface of tissue-factor-bearing cells and activated platelets, bypassing the haemostatic cascade and prompting initial fibrin clot formation. In addition, thrombin-mediated feedback reactions lead to activation of other coagulant components and to further platelet activation. Second, endogenous anti-tissue factor pathway inhibitors slow down the reactions on tissue-factor-bearing cells. Zymogen and procoagulant enzyme components of aPCC directly and indirectly amplify TG on activated platelet surfaces resulting in a burst of thrombin. Due to the long half-life of the zymogens, circulating substrate levels are elevated, leading to long-lasting haemostasis that prevents the recurrence of bleeds. Third, aPCC contains the natural clotting inhibitors protein C and protein S. A balanced increase in these factors down-regulates coagulation and, thus, might help to prevent thrombotic effects in absence of another procoagulant trigger. 38,42

**aPCC in the Management of PwHI**

aPCC has demonstrated control of bleeding episodes in clinical trials and in over 40 years of real-world usage in patients with congenital and acquired haemophilia with FVIII or FIX inhibitors across a range of ages, from toddlers to elderly patients, and in different clinical settings as on-demand, prophylactic, and concomitant with ITI therapy. 52–56 A post-authorisation safety study of PwHI receiving aPCC as prophylaxis or as on-demand treatment reported the occurrence of 3 treatment-related serious adverse events (AEs) in 3 (3.7%) patients and 6 treatment-related non-serious AEs in 5 patients (6.2%). One deep vein thrombosis was reported in an elderly patient; no other reports of thromboembolic events (TEEs) or thrombotic microangiopathy (TMAs). 28 A meta-analysis of studies in PwHIs reported no TEEs with long-term aPCC prophylaxis or under ITI regimen. 57 In this study, the incidence rate of TEEs for on-demand therapy was 5.09 (95% confidence interval [CI]: 0.01–1,795.6) per 100,000 infusions, and the pooled TEE incidence rate in congenital haemophilia patients was <0.01 per 100,000 infusions. 57 No TMAs have been reported with the use of aPCC as monotherapy to date. 48,58 Key clinical and real-world observational studies with aPCC are summarised in Table 2.

In line with the current approach to treatment, the Future of Immunotolerance Treatment (FIT) group recommends that all patients with inhibitors should be offered at least one attempt of ITI while under prophylaxis, using the existing management algorithm. 25 The group has proposed a hypothetical approach including non-factor therapies (NFTs), but recommends that prospective clinical studies are conducted to further explore the effect of combining these agents with FVIII in ITI. 25 As patients with inhibitors have a higher potential for bleeding-related death and additional daily burden, 59 all patients should be given the opportunity to eradicate inhibitors as it is the only proven regimen to restore patient response to FVIII, which is the fundamental deficiency. aPCC is part of the original ‘Bonn Protocol’, first conceived in the 1970s in Bonn, Germany, by Dr Hans-Hermann Brackmann for bleeding prevention during ITI. 54 The original protocol includes 100 IU FVIII/kg body weight and 50 U aPCC/kg body weight twice daily until the inhibitor titre decreased to <1 BU. 54 Proposed molecular mechanisms of ITI include T-cell exhaustion/anergy, inhibition of FVIII-specific memory B cell differentiation, formation of anti-idiotypic antibodies and, more recently, the generation of FVIII-specific regulatory T cells. 60,61 rFVIIa is often regarded as the preferred substance for treatment of...
| Reference (first author and year) | Study name | Study design | Inclusion criteria | N | Regimen/dose | Duration of treatment | Outcome |
|---------------------------------|------------|--------------|--------------------|---|--------------|----------------------|---------|
| Brackmann 1977<sup>53</sup>     | –          | Case study   | Patient with HA with inhibitors | 1 | ITI: initial 3,000 U FVIII + 2,500 U FIX daily, rising to 12,000 U FVIII daily for 10 d, then gradual reductions over 7 mo to 3,000 U FVIII + 1,000 FIX (aPCC) | 7 mo | No demonstrable inhibitor after 7 mo of treatment |
| Sjamsoedin 1981<sup>120</sup>   | –          | Randomised, double-blind, clinical | Patients with HA with inhibitors | 15 | On demand: 88 U/kg aPCC after bleed or prothrombin complex concentrate; then post 12 h for muscle bleed or post 6 h for mucocutaneous bleed, if necessary | 24 h | aPCC judged as ‘effective’ in 64% episodes; control judged as ‘effective’ in 52% episodes. Bleeding in the same joint and joint mobility significantly improved with aPCC vs. control (p = 0.0085 and p = 0.006, respectively) |
| Hilgartner 1983<sup>43</sup>    | –          | Open-label   | Patients with HA or HB and inhibitors aged ≥4 y | 49 (46 HA; 3 HB) | On demand: 50–70 U/kg aPCC at 12-h intervals | 72 h | 93% of 165 bleeding episodes in joints (102 episodes), mucous membranes (20 episodes), muscle and soft tissue (33 episodes), emergency episodes (10 episodes, 3 CNS bleeds and 4 surgical procedures) were controlled. 36% were controlled with 1 infusion in 12 h, 42% by ≥1 infusions in 36 h and 14% in >36 h. No serious side effects |
| Hilgartner 1990<sup>121</sup>   | –          | Uncontrolled; compared with earlier aPCC study | Patients with HA and inhibitors | 41 (106 bleeding episodes) | On demand: vapour-heated aPCC; 50 U/kg for mucous membrane bleeds, 75 U/kg for joint and muscle haemorrhages | Maximum: 36 h | 88% episodes were controlled, 79% within 36 h |
| Brackmann 1996<sup>54</sup>    | –          | Retrospective study | Patients with HA and inhibitors undergoing ITI | 81 | Prophylaxis under ITI: 100–150 IU/kg FVIII + 50 U/kg aPCC 2 × daily until <1 BU, then 150 IU/kg FVIII 2 × daily | Mean: 10–15 mo | For 22 patients with high responding inhibitors, time to <1 BU was 7 mo, and time to FVIII normalisation was 14.5 mo. For 15 moderate responders, time to <1 BU was 2.4 mo, and time to FVIII normalisation was 10.7 mo |
| Négrier 1997<sup>63</sup>      | –          | Multicentre retrospective study | Patients with HA or HB with inhibitors receiving aPCC | 60 | Prophylaxis: 65–510 U/kg/d aPCC, typically as 65–100 U/kg every 6–12 h | NA | Efficacy was judged as ‘good or excellent’ in 81.3% of episodes. Tolerance was assessed as ‘good’ in 98.8% of episodes. |

(Continued)
| Reference (first author and year) | Study name | Study design | Inclusion criteria | N | Regimen/dose | Duration of treatment | Outcome |
|----------------------------------|------------|--------------|--------------------|---|--------------|-----------------------|---------|
| Oldenburg 199952                 | –          | Open-label   | Patients with HA and inhibitors undergoing ITI | 60 | Prophylaxis under ITI: 100 IU/kg FVIII + 50 U/kg aPCC 2 × daily until < 1 BU; 150 IU/kg FVIII 2 × daily until no inhibitor detected and FVIII half-life normalised | Median (range) time to < 1B U: 5.4 (0.2–97.3) mo; to FVIII half-life normalisation: 14.1 (1.8–103.2) mo | Successful immune tolerance was achieved in 52 patients (86.7%); therapy failed in 8 patients (13.3%). The immune tolerance achieved was long-lasting in all 52 patients, with no inhibitor relapse in up to 20 y of follow-up |
| Ehrlich 2002122                  | –          | 10-y pharmacovigilance (all spontaneously reported thrombotic AEs) | Patients with inhibitors receiving aPCC | – | Safety: equivalent to 3.95 10^7 typical infusions distributed worldwide | – | 16 AEs documented over 10-y period (incidence of 4.05 per 10^5 infusions), DIC (n = 7) and myocardial infarction (n = 5) were the most frequent. One fatality in an 87-y-old metastatic cancer patient. In 13/16 (81%) patients, known risk factors were present (overdose, obesity, serum lipid abnormalities) |
| Bui 2002123                     | –          | Case study   | Post-surgical patient supported by ECMO treated with rFVIIa, then switched to aPCC | 1 | Post-surgery on demand: rFVIIa: 7.8 mg (90 μg/kg) then 4.8 mg. aPCC dose not recorded | NA | Patient died 20 min after aPCC treatment due to aPCC-precipitated thrombosis; clots were noted in the ECMO tubing |
| Rosenfeld 2002124               | –          | Case study   | Patients with severe HA and inhibitors receiving prolonged sequential aPCC and rFVIIa | 1 | On demand: aPCC 75 U/kg daily for 2 d then every 12 h for 1 d; then rFVIIa 90 μg/kg every 2 h for 2 d then every 6 h for 2 d; then aPCC 75 U/kg every 12 h | 14 d | Patient developed pulmonary embolism after sequential therapy |
| Dimichele 200648                | –          | Post-marketing surveillance study | Patients with HA and inhibitors receiving aPCC | 63 | NA | NA | >4, 500 infusions in 204 treatment courses in 63 patients. The incidence of AEs was low (<0.04%). No thrombotic complications were reported. Efficacy was considered good or excellent in 82% of acute treatments and 91% of surgeries |
| Astermark 200731                | FENOC     | Head-to-head, open-label, cross-over equivalency study of aPCC vs. rFVIIa | Patients with HA and inhibitors receiving aPCC | 48 | On demand: 1 dose of aPCC (75–100 U/kg; target dose, 85 U/kg) or 2 doses of rFVIIa (90–120 μg/kg; target dose, 105 μg/kg ×2) IV. Second dose of rFVIIa | NA | Efficacy 6 h post-infusion: aPCC and rFVIIa appear to exhibit a similar effect on joint bleeds, although the efficacy between products is rated differently by a substantial proportion of patients. |
| Reference (first author and year) | Study name | Study design | Inclusion criteria | N | Regimen/dose | Duration of treatment | Outcome |
|----------------------------------|------------|--------------|--------------------|---|--------------|-----------------------|---------|
| Schneiderman 2007<sup>125</sup>  | Retrospective chart review | Hospitalised children aged 18 mo to 16 y with severe refractory haemophilia and inhibitors | 4 (35 hospital admissions) | On demand: sequential (<6 h intervals) aPCC (32–80 U/kg) and rFVIIa (103–209 µg/kg) | 0.1–1.9 y at start of any therapy; 1.5–11.8 y at start of aPCC prophylaxis | CI for the differences in percentages of efficacy reported for each product only slightly exceeded the 15% boundary (−11.4 to −15.7%); p = 0.059 |
| Ettingshausen 2010<sup>64</sup> | Long-term prospective study | Paediatric patients (5.4–15 y) with HA and high-responding inhibitors who had failed, interrupted, or refused immune tolerance therapy | 7 | Prophylaxis: aPCC 50–100 U/kg, at frequencies from 3 times weekly up to twice daily | Mean annual spontaneous joint bleed incidence rate: 1.5 (95% CI: 0.7–3.0); no or mild osteoarthropathic alterations; no thrombotic complications, DIC or viral transmission |
| Leissinger 2011<sup>44</sup> | PRO-FEIBA Prospective, randomised, crossover study | Patients with HA >2 y of age, with high-titre inhibitors | 26 | Prophylaxis: 85 U/kg ± 15% aPCC on 3 non-consecutive d/wk On demand: 85 U/kg ± 15% aPCC | 6 mo | Mean 5.0 bleeding events on prophylaxis vs. 13.1 with on-demand treatment; representing a 62% reduction with prophylaxis vs. on-demand (p < 0.001). 16 (62%) patients had ≥50% reduction in bleeding events on prophylaxis (overall 84% reduction). Mean 5.0 bleeding events on prophylaxis vs. 13.1 with on-demand treatment; representing a 62% reduction with prophylaxis vs. on-demand (p < 0.001). 16 (62%) patients had ≥50% reduction in bleeding events on prophylaxis (overall 84% reduction) |
| Zülßkar 2012<sup>65</sup> | Multicentre registry study in Turkey | Patients with HA and inhibitors | 37 | On demand: median 50 U/kg aPCC every 12 h (acute bleeds), 100 U/kg aPCC every 12 h (surgical haemostasis) On demand: 85 U/kg aPCC | Median: 2 infusions | 112 treatment courses; 90 for acute bleeds, 22 for surgical haemostasis. Considered success in 92% of acute bleeds and 86% surgeries |
| Négrier 2013<sup>47</sup> | SURF Open-label, non-interventional, post-authorisation study | Patients undergoing surgical intervention with aPCC | 35 | Perioperative: 50–100 U/kg aPCC; not exceeding single dose of 100 U/kg or daily dose of 200 U/kg, 50–100 U/kg administered every | Varied | Haemostasis ‘good’ or ‘excellent’ in 91.2% of surgical procedures; ‘fair’ in 8.8% |

(Continued)
bleeds before and during ITI due to the potential for anamnestic response with aPCC, owing to the presence of trace amounts of FVIII that may promote a rise in inhibitor titre. An anamnestic response has been reported in up to 50% of patients treated with aPCC,45,63–65; nevertheless, no compromise in aPCC prophylactic efficacy has been reported, and inhibitor titres have been shown to reduce to expected levels.50,63–65 Registry reports successfull treatment in 50 to 80% of patients with HA66–69 and in 31% of patients with HB.67 Those patients who are not successfully tolerated or not directed to ITI are usually treated with prophylactic or on-demand doses of BPs and/or prophylactic NFTs.

The haemostatic efficacy of aPCC may be enhanced by dose optimisation, with dosage and duration of treatment being dependent on the location and extent of bleeding, the patient’s clinical condition and their response.70 A clearly defined unit of potency is required for dosage calculations and clinical management. The potency designation of aPCC is expressed in arbitrary units: 1 unit of aPCC shortens the activated partial thromboplastin time (aPTT) of FVIII inhibitor-containing reference plasma by 50%.58 Due to its mechanism of action, which concludes with TG, there is risk of thrombosis. To avoid this expected AE, the maximum daily dosage recommendation of aPCC for approved indications as monotherapy is 200 U/kg of body weight (100 U/kg per infusion).27 However, there are no standardised assays for the monitoring of response to BPs, and although global assays such as thromboelastography71 and TG assays72 can be useful to determine coagulation response, responses are typically evaluated by assessment of individual clinical response.

Two prospective studies assessing aPCC in the treatment of PwHI are on-going: FEIBA GO (FEIBA Global Outcome; EUPAS6691) and FEIBA STAR (FEIBA Reconstitution Volume Reduction and Faster Infusion Study; NCT02764489).

FEIBA GO is a prospective, non-interventional, multicentre cohort study in patients with HA or HB and high-responding inhibitors treated with aPCC, with a planned 4-year observation period. The study aims to assess the real-world haemostatic effectiveness and safety in individuals with aPCC treatment in routine clinical practice.73 Long-term prophylactic outcome data from a real-world setting will be captured in an attempt to address the lack of data in this patient group.

FEIBA STAR is a phase 3b/4, prospective, multi-centre, open-label, randomised, crossover study assessing the tolerability and safety of aPCC reconstituted in regular or 50% reduced volume and of faster infusion rates (4 and 10 U/kg/min, in comparison to the standard rate of 2 U/kg/min at the regular volume) in patients with HA or HB with inhibitors.74

### Table 2 (Continued)

| Reference (first author and year) | Study name | Study design | Inclusion criteria | N | Regimen/dose | Duration of treatment | Outcome |
|----------------------------------|------------|--------------|--------------------|---|-------------|----------------------|---------|
| Antunes 201446                  | PROOF      | Randomised comparison of on-demand vs. prophylactic aPCC | Patients with HA or HB and inhibitors receiving aPCC | 36 | Prophylaxis: 85 ± 15 U/kg aPCC every other day. On-demand: at discretion of investigator | 12 mo | Median ABR for on-demand: 28.7; prophylaxis: 7.9 (72.5% reduction) |
| Ewing 201550                   | –          | Retrospective chart review | Children aged ≤13 y with severe HA and inhibitors receiving aPCC prophylaxis | 16 | Prophylaxis: 70–100 IU/kg aPCC, 3–7 times weekly | Median range: 9 (2.6–20.5) y | AβR reduced from 4 (0–48) at baseline to 1 (0–7) after 1 y of prophylaxis |
| Négrier 201648                 | PASS       | Post-authorisation safety surveillance (real-world study) | Patients with HA or HB and inhibitors receiving aPCC for 1 y | 81 | Prophylaxis: mean (SD) 80.5 (27.8) U/kg/d aPCC On-demand: mean (SD) 104.9 (41.9) U/kg/d aPCC | 12 mo | Haemostatic effectiveness judged as ‘good/excellent’ in 90.1% patients |
| Windyga 201927                 | FEIBA GO   | Observational study | Patients with congenital HA and inhibitors | 53 | Prophylaxis: median (range) 61.0 (50–98) U/kg per infusion aPCC On-demand: median (range) 56.8 (2.3–62.5) U/kg per infusion aPCC | 12 mo | Mean (SD) ABR for patients with >12 mo follow-up: prophylaxis (n = 21): 7.1 (9.3); on-demand (n = 6): 11.4 (12.8). Mean (SD) AβR: prophylaxis (n = 21): 4.2 (5.1); on-demand (n = 6): 7.3 (7.9) |

Abbreviations: ABR, annualised bleeding rate; AE, adverse event; AJBR, annualised joint bleeding rate; aPCC, activated prothrombin complex concentrate; CI, confidence interval; DIC, disseminated intravascular coagulation; ECMO, extracorporeal membrane oxygenation; FEIBA, factor eight inhibitor bypass activity; HA, haemophilia A; HB, haemophilia B; ITI, immune tolerance induction; IV, intravenous; NA, not applicable; PwHI, patients with haemophilia and inhibitors; rFVIIa, recombinant activated factor VIIa; SD, standard deviation.
The aim of the study is to clarify if reducing infusion volumes and accelerating infusion rates for aPCC will lead to increased adherence to aPCC prophylaxis.

**Non-Factor Therapies**

Despite the beneficial results of BPAs, efficacy can be inconsistent, and a subset of patients on prophylactic therapy show a poor response.\(^{75}\) This has prompted the development of NFTs, with alternative mechanisms of action that aim to offer treatment options that are long-acting, subcutaneously administered, and efficacious irrespective of the presence of inhibitors.

To date, only one NFT – emicizumab (Hemlibra; Roche, Basel, Switzerland) – has been approved for routine prophylaxis to prevent or reduce the frequency of bleeding episodes in patients with congenital HA with (U.S. Food and Drug Administration [FDA] 10/2017, European Medicines Agency [EMA] 2/2018) or without FVIII inhibitors for HA of any severity (FDA 10/2018) or for severe HA only (EMA 3/2019).\(^{76}\) Emicizumab is a bi-specific monoclonal immuno-globulin G antibody that bridges activated FIX and FX to replace the function of missing activated FVIII, thereby enhancing coagulation and restoring haemostasis.\(^{77}\) With a half-life of approximately 30 days, emicizumab is suitable for once weekly, fortnightly or monthly prophylaxis,\(^{78}\) and has demonstrated prevention of bleeds in patients with inhibitors in clinical studies. In a phase 3 trial in adult PwHI, once-weekly emicizumab prophylaxis was associated with a lower rate of treated bleeding events compared with no prophylaxis (2.9 [95% CI: 1.7–5.0] vs. 23.3 events [95% CI: 12.3–43.9]).\(^{79}\) However, limited data are available for perioperative use.

Although some case studies report the successful use of emicizumab prophylaxis in conjunction with perioperative rFVIIa,\(^{80–83}\) there is a lack of suitable assays for BPAs and emicizumab that allow the precise monitoring of coagulation and treatment response, necessary to guide therapy when undertaking surgical procedures.\(^{71,72,84,85}\) aPTT-based clotting assays, which determine FVIII activity, are not suitable for the estimation of clotting with emicizumab when used in conjunction with BPAs, because the assay is unable to reflect the combined effect on thrombin by these products, and the sensitivity of thromboelastography is currently not sufficient for guiding therapy. However, correlations between the clinical bleeding phenotype of patients and their TG capacity have been demonstrated, and as thrombin is the final product generated by combined treatment with these products, it has been proposed that the TG assay might be a more relevant test for monitoring and guiding therapy using these regimens. A three-step protocol using TG assay has been proposed to individually tailor bypassing therapy and thereby limit AEs that may occur when combining with emicizumab.\(^{86–89}\)

A second consideration concerns the safety of the patients receiving emicizumab concomitantly with other haemostatic agents, like BPAs, for breakthrough bleeds. Despite high efficacy rates with emicizumab prophylaxis, 36% of patients still experienced breakthrough bleeds that may have required additional treatment.\(^{90}\) However, a potential synergistic and cumulative effect between emicizumab and aPCC is thought to exist.\(^{91}\) While emicizumab acts by bridging activated FIX (FIXa) and FX, allowing the coagulation cascade to continue, aPCC increases the availability of FIX/FIXa. The combination of both agents, utilising different mechanisms of action, can result in excessive TG and increased thrombosis risk.\(^{91}\) In HAVEN 1, a phase 3 trial of emicizumab prophylaxis in adult PwHI, TMA was reported in three patients and TEE in two patients (cavernous sinus thrombosis and skin necrosis–superficial thrombophlebitis) who received concurrent therapy with emicizumab and aPCC for breakthrough bleeding (cumulative dose >100 U/kg/day aPCC for more than 24 hours).\(^{92}\) Two of the three patients who developed TMA received both rFVIIa and aPCC (one patient received rFVIIa first then rFVIIa, the other patient received aPCC first then rFVIIa). The authors concluded that the TMA events were driven by the synergistic effects of high cumulative doses of aPCC in combination with emicizumab. Considering the absence of report of such AEs in this population (TMA has not previously been reported with emicizumab alone in >5,200 patients as of September 2019, including >350 patients enrolled in clinical studies as of April 2017,\(^{93}\) or with aPCC alone to date\(^{49,58,94,95}\), it has been inferred that the risk of TMA is likely to arise from novel interactions between aPCC and emicizumab\(^{96}\) and most likely represents a mechanism distinct from the known processes leading to TMA.\(^{92}\) Indeed, in vitro experiments with aPCC and a sequence-identical analogue of emicizumab show elevated procoagulant activity demonstrated by excessive TG with combinations of aPCC and sequence-identical analogue of emicizumab at clinically relevant doses.\(^{91}\) In HAVEN 1, all TEEs occurred with concomitant aPCC and emicizumab using aPCC at doses of >100 U/kg/day for >24 hours. In contrast, no events occurred with lower-dose aPCC or for treatment durations ≤24 hours, which is now the recommended dose when used to treat patients receiving emicizumab.\(^{93}\) In contrast to TMAs, TEEs have also been observed with emicizumab-treated patients who are not receiving aPCC. As of March 31, 2020, 18 cases of TEEs have been reported in patients receiving emicizumab in any setting (including in patients without inhibitors), two of which included concomitant use of aPCC exceeding 100 U/kg/day.\(^{24,97}\) The use of aPCC or other haemostatic agents is unknown in the 16 additional cases. One case was reported from HAVEN 3, the phase 3 clinical trial of emicizumab for the treatment of patients with HA without inhibitors. Further clinical experience and additional research are needed to more fully elucidate the safety implications of integrating different therapies into the existing treatment landscape for PwHI.

**Other Therapies in Development**

Other NFTs in development are summarised in Table 3 and include anti–tissue factor pathway inhibitors, aptamers and small interfering RNA directed against anti-thrombin III. One study points toward a benefit with concomitant use of
### Table 3: Therapies in development for use in PwHI

| Drug name | Manufacturer | Approach | Development status<sup>a</sup> | Administration | Dose (prophylaxis) | Half-life | Laboratory parameters | Potential indications |
|-----------|--------------|----------|--------------------------------|----------------|-------------------|----------|-----------------------|----------------------|
| Concizumab | Novo Nordisk (Bagvaerd, Denmark) | Antibody inhibiting TFPI | Phase 3 (explorer 7) (NCT04083781; study start Oct 21, 2019) | SC | TBD (evaluated range: 0.25–0.8 mg/kg every 4 d) | 2.91–3.95 h | Elevated D-dimer, soluble fibrin and prothrombin F<sub>1+2</sub> with 0.8 mg/kg dose. Decreased fibrinogen with 0.5 and 0.8 mg/kg doses. No significant changes in platelet counts, antithrombin levels, prothrombin time, aPTT, protein C and protein S | Treatment of haemophilia A or B with or without inhibitors |
| Fitusiran | Alnylam Pharmaceuticals (Cambridge, Massachusetts, United States) and Sanofi Genzyme (Cambridge, Massachusetts, United States) | siRNA-targeting antithrombin | Phase 3 (NCT03549871, study start July 30, 2018; NCT03574790, study start Jan 9, 2019; NCT03417102, study start Feb 14, 2018) | SC | TBD (evaluated range: 0.25–9.0 mg/kg; IV) | 2.6–5.3 h | Elevated liver enzymes | Prevent bleeding episodes in patients with haemophilia A or B |
| Marstacimab (PF-06741086)<sup>2</sup> | Pfizer (New York, New York, United States) | Antibody inhibiting TFPI | Phase 3 (NCT0338792, study start Oct 2019) | SC | TBD (evaluated range: 150–450 mg) | ND | ND | Treatment of haemophilia A and haemophilia B with and without inhibitors |
| BAY 109384<sup>13</sup> | Bayer (Leverkusen, Germany) | Antibody inhibiting TFPI | Phase 2 (NCT03597022, study start July 24, 2018) | SC and IV | TBD | ND | ND | Severe haemophilia A or B with or without inhibitors |
| Eptacog alfa (AryoSeven)<sup>14</sup> | AryoGen (Tehran, Iran) | Activated factor VIIa (biosimilar) | Phase 3 (NCT03935334, study start July 23, 2018) | IV | 90–270 µg/kg | ND | ND | Haemophilia A or B with inhibitors |
| MC710<sup>5</sup> | KM Biologics/Kaketsukin (Kumamoto, Japan) | Activated factor VIIa/FX | Phase 3 | IV | 60 or 120 µg/kg | MC710 components: FVII:C 1.8–2.3 h, FVII:Ag 1.8–2.6 h, FX:Ag 15.8–16.0 h, FX:Ag 22.5–26.5 h<sup>11</sup> | Elevated D-dimer, TAT and prothrombin F<sub>1+2</sub>, no change in platelet count, fibrinogen | Haemophilia A or B with inhibitors |
| Marzeptacog alfa (MarzAA)<sup>16</sup> | Catalyst Biosciences (San Francisco, CA, United States) | Activated factor VIIa | Phase 2/3 (NCT03407651, study start Dec 18, 2017) | SC | TBD | 3.5 h (terminal) | ND | Haemophilia A or B with inhibitors |
| Eptacog beta<sup>17</sup> | HEMA Biologics/LFB-USA (Framingham, Massachusetts, United States) | Recombinant coagulation factor VIIa | Phase 3 (NCT02448680, study start Dec 2015) | IV | TBD (evaluated doses: 75 and 225 µg/kg) | 1.8–2.3 h (terminal)<sup>12</sup> | ND | Haemophilia A or B with inhibitors |
| SPK-8016<sup>18</sup> | SPARK Therapeutics (Philadelphia, Pennsylvania, United States) | AAV5 viral vector gene therapy | Phase 2/3 (NCT03734588, study start Jan 30, 2019) | IV | TBD (single dose) | ND | ND | Haemophilia A with inhibitors |
| AMT-180<sup>19</sup> | uniQure (Amsterdam, Netherlands) | AAV5 viral vector gene therapy with modified factor IX gene (Super9) | Preclinical | IV | TBD (single dose) | ND | ND | Haemophilia A with or without inhibitors |

Abbreviations: AAV, adeno-associated virus; aPTT, activated partial thromboplastin time; IV, intravenous; ND, no data; SC, subcutaneous; TAT, thrombin–antithrombin complex; TBD, to be determined; TFPI, tissue factor pathway inhibitor.

<sup>a</sup>Status as of November 7, 2019.
fitusiran and aPCC, with reported dosages of aPCC of 14 to 75 U/kg (13 infusions for 6 bleeds in 3 patients; mean of 2.2 infusions per bleed) and rFVIIa of 93 to 133 µg/kg (6 infusions for 4 bleeds in 3 patients; mean of 1.5 infusions per bleed). No complications were reported in this study, although a sinus vein thrombosis had occurred in a fitusiran-treated patient receiving repeated infusions of FVIII product,12 which is suggestive of similar concerns of synergistic and cumulative effects as seen with emicizumab and concomitant aPCC. In vitro and in vivo studies suggest a therapeutic benefit with concomitant concizumab and low-dose aPCC,99,100 and a synergistic haemostatic effect was reported with concomitant concizumab and rFVIIa in human blood under haemophilia conditions,101 but further data are required.

Several rFVIIa compounds are in development for PwHI (Table 3). An rFVIIa biosimilar protease, activated eptacog alpha (Coagil-VII; Generium), has been approved for PwHI undergoing surgery in Russia.102 However, very little clinical data have been published to date. A series of case studies with the substance reported about the experience of 10 patients given Coagil-VII after switching from NovoSeven. There were therapeutic failures in four patients and allergic reactions in two patients, for whom it was necessary to revert to NovoSeven, and a good clinical response was achieved in those patients.103 A second rFVIIa biosimilar is in development in PwHI (AryoSeven; Aryogen), with a similar response to rFVII (NovoSeven) reported in a clinical study.104

Another FVIIa product, MC710, being developed by the Chemo-Sero Therapeutic Research Institute (Japan), is a 1:10 protein weight ratio mixture of plasma-derived activated FVIIa and FX.105 In a phase 3, open-label study of 21 joint, muscle and subcutaneous bleeding episodes in 14 male patients, individuals received one or two doses of intravenously administered MC710 at 60 or 120 µg/kg once or twice (to a maximum of 180 µg/kg) for up to five bleeding episodes per patient. Nineteen episode treatments were rated ‘excellent’ or ‘effective’ 8 hours after the last treatment.105

The rFVIIa variant marzeptacog alfa (MarzAA; Catalyst Biosciences) was designed to combine higher clot-generating activity and longer activity at the site of bleeding and therefore improve efficacy.106 It is anticipated that the compound could be used for both subcutaneous prophylactic treatment and intravenous acute treatment, and may be valuable for patients with HB with inhibitors, or patients with HA with inhibitors who failed emicizumab.107,108 The compound has achieved orphan status and is currently in phase 2 trials for patients with HA or HB with inhibitors; nine patients with high annual bleeding rates (ABRs) before the study (15.2–26.7 bleeds per year) have successfully completed long-term daily dosing with the compound. Seven participants experienced no bleeds with a 30-µg/kg dose and two others who escalated their dose to 60 µg/kg had clinically significant reductions in ABR and proportion of days with bleeding. No anti-drug antibodies were detected, but further safety data are needed.109

Eptacog beta (LR769; Hema Biologics/LFB) is a transgenic recombinant human FVIIa produced in rabbits and approved by FDA on April 1, 2020 for the treatment of bleeding episodes in HA or HB patients with inhibitors.110 In a pivotal phase 3 study of two initial dose regimens in 468 bleeding events in 27 PwHIs, both study arms met the primary endpoint of haemostatic success (evidence of cessation of bleeding).110 The majority (85%) of the bleeding events treated with the initial 225-µg/kg dose required no further therapy. Currently, two additional phase 3 trials are investigating the use of eptacog beta in paediatric and surgical PwHIs.111

Encouraging results from clinical trials have also stimulated considerable interest in the application of gene therapy for the treatment of haemophilia, using in vivo gene transfer to the liver using adeno-associated viral vectors. Results from recent clinical trials suggested some therapeutic expression, and in some cases a curative effect.112 Although the presence or history of inhibitors has until recently been considered an exclusion criterion for studies with gene therapy for haemophilia,113 gene therapy trials are now underway for haemophilia patients with inhibitors. These include SPK-8016 (Spark Therapeutics), in phase 1/2 development for patients with HA and inhibitors,114 and AMT-180 (uniQure), in preclinical development for patients with HA with past or current inhibitors.114

Use of aPCC in PwHIs in the Evolving Treatment Landscape

As we enter an era of therapies for PwHIs with higher efficacy for prophylaxis, the use of BPAs is expected to decrease in such clinical settings.115 However, the use of aPCC is still recommended in recent treatment guidelines for haemophilia.3–7 Various scenarios in which the use of aPCC may remain necessary include (1) treatment of breakthrough bleeds or (2) as surgical prophylaxis in patients under NFT prophylaxis. Findings from the HAVEN 1 trial and the interim analysis of the STASEY study indicate that up to 37% of patients still experienced bleedings.31,92 Recent data, supported by clinical experience, indicate that aPCC < 50 U/kg is sufficient to fully restore TG and has been shown to elicit a good clinical response.24,85,116–119 (3) When following high-dose ITI regimens, such as the Bonn Protocol. For example, there are currently insufficient data to fully understand whether high-dose ITI is compatible with emicizumab; therefore, until such evidence becomes available, aPCC may represent an alternative to emicizumab as prophylaxis when on an ITI regimen. (4) For treatment of acute bleeding while following an ITI protocol with addition of emicizumab, where use of aPCC (lower dose) or rFVIIa is essential. (5) Patients with HB with inhibitors, and (6) patients with acquired HA,25 for whom emicizumab is not indicated.76 (7) Well-controlled patients who achieve ≥50% reduction in the number of bleeds44 under a current aPCC prophylaxis regimen, e.g. patients with an ABR of <4 per year, or patients who have succeeded with ITI. (8) On-demand treatment in low income and developing countries, where access to new products may be limited (Table 4).
Table 4 Scenarios for use of aPCC in the evolving treatment landscape

|   |                                                                                           |
|---|--------------------------------------------------------------------------------------------|
| 1 | Treatment of breakthrough bleeds in patients receiving NFT prophylaxis                      |
| 2 | Surgical prophylaxis in patients receiving NFT                                             |
| 3 | Prophylaxis while on high-dose ITI                                                        |
| 4 | Treatment of acute bleeds while under ITI                                                  |
| 5 | Patients with haemophilia B with inhibitors                                               |
| 6 | Patients with acquired haemophilia A                                                       |
| 7 | Well-controlled patients achieving ≥50% reduction in bleeds with aPCC or with ABR/AJBR < 4 |
| 8 | On-demand treatment in low-income and developing countries with limited access to treatment |

Abbreviations: ABR, annualized bleeding rate; AJBR, annualised joint bleeding rate; aPCC, activated prothrombin complex concentrate; ITI, immune tolerance induction; NFT, non-factor therapies.

Conclusions

Since the 1970s, aPCC has been used for the treatment and prevention of acute bleeds in PwHIs and, later with rFVIIa, became standard of care. Even after more than 40 years, aPCC has a continuing role in the treatment of acute bleeds, prophylaxis, and surgical management in this patient group. Its most notable uses are for prophylaxis in patients for whom emicizumab is not available or applicable, for patients initially receiving rFVIIa who do not respond to treatment, and for low-dose treatment of breakthrough bleeds or surgery. However, there remains a need for alternative treatments for breakthrough bleeding (either spontaneous or post-trauma) and surgical applications that do not carry a risk of excess TG with concomitant usage with prophylactic treatment. As further data are generated with the newer therapeutic molecules and gene therapies for PwH, there will be a need to identify the patient profiles that benefit most from each treatment, or combinations of treatments, for example, with the use of surrogate markers of haemostasis to enable selection of a suitable management strategy. Understanding the potential risks of unanticipated AEs when integrating new therapies into the treatment armamentarium is vital, as already observed with the integration of emicizumab with aPCC. Consequently, there is a need for further exploration of potential synergistic effects between agents, of dose-ranging for the avoidance of TMA and other thrombotic risks, and for monitoring studies of combination therapies with aPCC. Considering inter-patient variability, it will be important for all haemostatic agents to remain available, with recommendations on how to use them, to ensure optimal treatment and for prevention of bleeding episodes as well as patient safety.

Authors’ Contributions

All authors jointly conceived the idea for the review. All authors contributed to writing of the manuscript, and all authors critically reviewed the manuscript at each stage of development.

Funding

This study was supported by Baxalta US Inc., a Takeda company.

Conflict of Interest

Hans Hermann Brackmann has received honoraria for presentations from Takeda, Sobi and Roche. Wolfgang Schramm has participated in advisory boards for Biotest, and received honoraria for lectures from Bio&Bio AG, Biotest, Novo, Roche and Shire, a Takeda company. Johannes Oldenburg has received grant/research support from Bayer, Biotest, CSL Behring, Novo Nordisk, Octapharma, Pfizer and Shire, a Takeda company, and fees for consultancy and speakers bureaus from Bayer, Biogen, Biotest, Chugai, CSL Behring, Grifols, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, a Takeda company, and Sobi. Viridiana Cano was an employee of Shire GmbH, a Takeda company, Zürich, Switzerland during the development of this review and a stockholder in Takeda Pharmaceutical Company Limited. Peter Turecek is an employee of Baxalta Innovations GmbH, a Takeda company, Vienna, Austria and a stockholder in Takeda Pharmaceutical Company Limited. Claude Négrier has received grant/research support from CSL Behring, Octapharma, Shire, a Takeda company, and Sobi; fees for consultancy from Alnylam, Bayer, CSL Behring, LFB, Novo Nordisk, Octapharma, Pfizer, Roche, Shire, a Takeda company, and Sobi; and as a paid instructor for Novo Nordisk.

Acknowledgements

The authors would like to thank Berthold Senturs and Christopher Anson, Baxalta, a Takeda company, Vienna, Austria, for their assistance in compiling the source literature for this review. Under the direction of the authors, medical writing support was provided by Tina Morley, BSc, and Lindsay Napier, PhD, CMP, employees of Excel Medical Writing, Austria, for their assistance in compiling the source literature. The authors would like to thank Berthold Senturs and Christopher Anson, Baxalta, a Takeda company, Vienna, Austria, for their assistance in compiling the source literature for this review. Under the direction of the authors, medical writing support was provided by Tina Morley, BSc, and Lindsay Napier, PhD, CMP, employees of Excel Medical Affairs (Fairfield, Connecticut, United States) and was funded by Baxalta US Inc., a Takeda company, Lexington, Massachusetts, United States.

References

1 Bowen DJ. Haemophilia A and haemophilia B: molecular insights. Mol Pathol 2002;55(02):127–144
2 Soucie JM, Cianfrini C, Janco RL, et al. Joint range-of-motion limitations among young males with hemophilia: prevalence and risk factors. Blood 2004;103(07):2467–2473
3 Brackmann HH, Lenk H, Scharrer L, Auerswald G, Kreuz W. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 1999;5(03):203–206
4 Collins PW, Chalmers E, Hart DP, et al; UK Haemophilia Centre Doctors Organization. Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition). Br J Haematol 2013;160(02):153–170
5 Rocino A, Coppola A, Franchini M, et al; Italian Association of Haemophilia Centres (AICE) Working Party. Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfus 2014;12(04):575–598
6 Srivastava A, Brewer AK, Mauser-Bunschoten EP, et al; Treatment Guidelines Working Group on Behalf of The World Federation of Hemophilia. Guidelines for the management of hemophilia. Haemophilia 2013;19(01):e1–e47
7 Valentino LA, Kempton CL, Kruse-Jarres R, Mathew P, Meeks SL, Reiss UM; International Immune Tolerance Induction Study Investigators. US guidelines for immune tolerance induction in patients with haemophilia a and inhibitors. Haemophilia 2015;21(05):559–567
8 Manco-Johnson MJ, Abshire TC, Shapiro AD, et al. Prophylaxis versus episodic treatment to prevent joint disease in boys with severe hemophilia. N Engl J Med 2007;357(06):535–544
9 Usuka K, Price VE, Blanchette V, et al. Impact of prophylaxis on health-related quality of life of boys with hemophilia: an analysis of pooled data from 9 countries. Res Pract Thromb Haemost 2019;3(03):397–404
10 Björkman S, Population pharmacokinetics of recombinant factor IX: implications for dose tailoring. Haemophilia 2013;19(05):753–757
11 Björkman S, Folkesson A, Jönsson S. Population pharmacokinetics of factor VIII in the age range 3–74 years: a population analysis based on 50 patients with long-term prophylactic treatment for haemophilia A. Eur J Clin Pharmacol 2009;65(10):989–998
12 Nogami K, Shima M. New therapies using nonfactor products for patients with hemophilia and inhibitors. Blood 2019;133(05):399–406
13 Ehrenforth S, Kreuz W, Scharrer I, et al. Incidence of development of factor VIII and factor IX inhibitors in haemophiliacs. Lancet 1992;339(8793):594–598
14 Caraco M, Goudemand J. Inhibitors in haemophilia: a primer. 5th ed. Montreal World Federation of Hemophilia 2018. Available at: http://www1.wfh.org/publication/files/pdf-1122.pdf. Accessed January 2, 2020
15 Chitlur M, Warrier I, Rajpurkar M, Lusher JM. Inhibitors in factor IX deficiency: a report of the ISTH-SSC international FIX inhibitor registry (1997–2006). Haemophilia 2009;15(05):1027–1031
16 Ewenstein BM, Takemoto C, Warrier I, et al. Nephrotic syndrome as a complication of immune tolerance in hemophilia B. Blood 1999;89(03):1115–1116
17 Astemark J. Inhibitor development: patient-determined risk factors. Haemophilia 2010;16(10):66–70
18 Astemark J, Alisent C, Batorova A, et al; European Haemophilia Therapy Standardisation Board. Non-genetic risk factors and the development of inhibitors in haemophilia: a comprehensive review and consensus report. Haemophilia 2010;16(05):747–766
19 Gouw SC, Fijnvandraat K. Identifying nongenetic risk factors for inhibitor development in severe hemophilia a. Semin Thromb Hemost 2013;39(07):740–751
20 Kempton CL, White GC II. How we treat a hemophilia A patient with a factor VIII inhibitor. Blood 2009;113(01):11–17
21 Rocino A, Franchini M, Coppola A. Treatment and prevention of bleeds in hemophilia patients with inhibitors to factor VIII/IX. J Clin Med 2017;6(04):E46
22 Eckhardt CL, Loomans JI, van Velzen AS, et al; INSIGHT Study Group. Inhibitor development and mortality in non-severe hemophilia A. J Thromb Haemost 2015;13(07):1217–1225
23 Walsh CE, Sourie JM, Miller CH; United States Hemophilia Treatment Center Network. Impact of inhibitors on hemophilia A mortality in the United States. Am J Hematol 2015;90(05):400–405
24 National Hemophilia Foundation. Recommendation on the use and management of emicizumabXXWH (Hemlibra(r)) for hemophilia A with and without inhibitors. Available at: https://www.hemophilia.org/sites/default/files/document/files/258_emicizumab.pdf. Published 2020. Accessed May 12, 2020
25 Carcao M, Escuriola-Ettingshausen C, Santagostino E, et al; Future of Immunotolerance Treatment Group. The changing face of immune tolerance induction in haemophilia A with the advent of emicizumab. Haemophilia 2019;25(04):676–684
26 Kempton CL, Meeks SL. Toward optimal therapy for inhibitors in hemophilia. Blood 2014;124(23):3365–3372
27 Shire Pharmaceuticals Limited. FEIBA summary of product characteristics. Available at: https://www.medicines.org.uk/emc/product/9192/smpc. Published 2019. Updated January 24, 2019. Accessed January 2, 2020
28 Négrier C, Voisin S, Baghaei F, et al; FEIBA PASS Study group. Global Post-Authorization Safety Surveillance Study: real-world data on prophylaxis and on-demand treatment using FEIBA (an activated prothrombin complex concentrate). Blood Coagul Fibrinolysis 2016;27(05):551–556
29 Novo Nordisk Limited. NovoSeven 1 mg (50KIU) powder and solvent for solution for injection: Summary of Product Characteristics. Available at: https://www.medicines.org.uk/emc/product/6360/smpc#DOCREVISION. Published 2018. Accessed January 2, 2020
30 Matino D, Makris M, Dwan K, D’Amico R, Iorio A. Recombinant factor VIII concentrate versus plasma-derived concentrates for treating acute bleeding episodes in people with haemophilia and inhibitors. Cochrane Database Syst Rev 2015;(12):CD004449
31 Astemark J, Donfield SM, DiMichele DM, et al; FENOC Study Group. A randomized comparison of bypassing agents in hemophilia complicated by an inhibitor: the FEIBA NovoSeven Comparative (FENOC) Study. Blood 2007;109(02):546–551
32 Breen FA Jr, Tullis JL. Prothrombin concentrates in treatment of Christmas disease and allied disorders. JAMA 1969;208(10):1848–1852
33 deWitt RT, Feinstein DI. Prothrombin complex concentrate. Arch Intern Med 1977;137(09):1211–1213
34 Kurzynski EM, Penner JA. Activated prothrombin concentrate for patients with factor VIII inhibitors. N Engl J Med 1974;291(04):164–167
35 Sultan Y, Brouet JC, Debre P. Letter: Treatment of inhibitors to factor VIII with activated prothrombin concentrate. N Engl J Med 1974;291(20):1087
36 Kelly P, Penner JA. Antihemophilic factor inhibitors. Management with prothrombin complex concentrates. JAMA 1976;236(18):2061–2064
37 Prowse CV. Activated prothrombin complex concentrates: approaches to their preparation. Thromb Res 1982;22(05):231–218
38 Turecek PL, Váradi K, Schwarz HP. Update on the mechanism of action and future of activated prothrombin complex concentrates. CurrHematol Rep 2004;3(05):331–337
39 Négrier C, Gomperts ED, Oldenburg J. The history of FEIBA: a lifetime of success in the treatment of haemophilia complicated by an inhibitor. Haemophilia 2006;12(55):4–13
40 Shire. FEIBA (anti-inhibitor coagulant complex) for intravenous use, lyophilized powder for solution [Prescribing Information]. Available at: https://www.shirecontent.com/PDFs/FEIBA_U- SA_ENG.pdf. Published January 1, 2019. Accessed January 2, 2020
41 Varadi K, Tangada S, Loeschberger M, et al. Pro- and anticoagulant factors facilitate thrombin generation and balance the haemostatic response to FEIBA® in prophylactic therapy. Haemophilia 2016;22(04):615–624
42 Turecek PL, Váradi K, Gritsch H, Schwarz HP. FEIBA: mode of action. Haemophilia 2004;10(Suppl 2):3–9
43 Hilgartner MW, Knatterud GL. The use of factor eight inhibitor bypassing activity (FEIBA immuno) product for treatment of bleeding episodes in hemophilia complicated by an inhibitor. Haemophilia 2005;12(55):4–13
44 Leissinger C, Gringeri A, Antmen B, et al. Anti-inhibitor coagulant complex prophylaxis in hemophilia with inhibitors. N Engl J Med 2011;365(18):1684–1692
45 Zühlkik B, Aydogan G, Salcioglu Z, et al; FEIBA Investigators Team. Efficacy of FEIBA for acute bleeding and surgical haemostasis in haemophilia A patients with inhibitors: a multicentre registry in Turkey. Haemophilia 2012;18(03):383–391
aPCC in Congenital Haemophilia with Inhibitors

DiMichele D. Inhibitor development in haemophilia B: an orphan disease in need of attention. Br J Haematol 2007;138(03):305–315.

Négrier C, Lienhart A, Numerof R, et al. SURgical interventions with FEIBA (SURF): international registry of surgery in haemophilia patients with inhibitory antibodies. Haemophilia 2013;19(03):e143–e150.

Dimichele D, Négrier C. A retrospective postlicensure survey of FEIBA efficacy and safety. Haemophilia 2006;12(04):352–362.

Ewinger N, Escuriela-Ettinghausen C, Kreuz W. Prophylaxis with FEIBA in paediatric patients with haemophilia A and inhibitors. Haemophilia 2015;21(03):358–364.

Nakar C, Manco-Johnson MJ, Lail A, et al. Prompt immune tolerance induction at inhibitor diagnosis regardless of titre may increase overall success in haemophilia A complicated by inhibitors: experience of two U.S. centres. Haemophilia 2015;21(03):365–373.

Oldenburg J, Schwaab R, Brackmann HH. Induction of immune tolerance in haemophilia A inhibitor patients by the ‘Bonn Protocol’: predictive parameter for therapy duration and outcome. Vox Sang 1999;77(01, Suppl 1):49–54.

Brackmann HH, Gormsen J. Massive factor-VIII infusion in haemophilicac with factor-VIII inhibitor, high responder. Lancet 1977;2(8644):933.

Brackmann HH, Oldenburg J, Schwaab R. Immune tolerance for the treatment of factor VIII inhibitors—twenty years ‘bonn protocol’. Vox Sang 1996;70(01, Suppl 1):30–35.

Brackmann HH. Induced immunotolerance in factor VIII inhibitor patients. ProgClinBiol Res 1984;180:150–181.

Zeitzer H, Ulrich-Merzenich G, Hess L, et al. Treatment of acquired haemophilia by the Bonn-Malmo Protocol: documentation of an in vivo immunomodulating concept. Blood 2005;105(06):2287–2293.

Rota M, Cortesi PA, Crea R, Gringeri A, Mantovani LG. Thrombo-embolic event rate in patients exposed to anti-inhibitor coagulant complex: a meta-analysis of 40-year published data. Blood Adv 2017;1(26):2637–2642.

Luu H, Ewenstein B. FEIBA safety profile in multiple modes of clinical and home-therapy application. Haemophilia 2004;10(06):2287–2293.

duFrei S. Physical and psychosocial challenges in adult hemophilia patients with inhibitors. J Blood Med 2014;5:115–122.

Waters B, Lillicrap D. The molecular mechanisms of immunomodulation and tolerance induction to factor VIII. J ThrombHaemost 2009;7(09):1446–1456.

Kim YC, Zhang AH, Su Y, et al. Engineered antigen-specific human regulatory T cells: immunosuppression of FVIII-specific T- and B-cell responses. Blood 2015;125(07):1107–1115.

Giagrande PLE, Hermans C, O’Mahony B, et al. European Haemophilia Consortium (EHC) and the European Association for Haemophilia and Allied Disorders (EHAAD). European principles of inhibitor management in patients with haemophilia. Orphanet J Rare Dis 2018;13(01):66.

Négrier C, Goudemand J, Sultan Y, Bertrand M, Rothschild C, Lauroua P. Multicenter retrospective study on the utilization of FEIBA in France in patients with factor VIII and factor IX inhibitors. French FEIBA Study Group. Factor Eight Bypassing Activity. ThrombHaemost 1997;77(06):1113–1119.

Ettinghausen CE, Kreuz W. Early long-term FEIBA prophylaxis in haemophilia A patients with inhibitor after failing immune tolerance induction: a prospective clinical case series. Haemophilia 2010;16(01):90–100.

Zanon E, Pasca S, Santoro C, et al. Activated prothrombin complex concentrate (FEIBA®) in acquired haemophilia A: a large multi-centre Italian study - the FAIR Registry. Br J Haematol 2019;184(05):853–855.

Coppola A, Margaglione M, Santagostino E, et al; AICE PROFIT Study Group. Factor VIII gene (F8) mutations as predictors of outcome in immune tolerance induction of haemophilia A patients with high-responding inhibitors. J ThrombHaemost 2009;7(11):1809–1815.

DiMichele DM, Kroner BL; North American Immune Tolerance Study Group. The North American Immune Tolerance Registry: practices, outcomes, outcome predictors. ThrombHaemost 2002;87(01):52–57.

Lenk H; ITT Study Group. The German Registry of immune tolerance treatment in hemophilia—1999 update. Haematologica 2000;85(10, Suppl):45–47.

Mariani G, Kroner B; Immune Tolerance Study Group (ITSC). Immune tolerance in hemophilia with factor VIII inhibitors: predictors of success. Haematologica 2001;86(11):1186–1193.

Shapiro AD, Hedner U. Advances in bypassing agent therapy for hemophilia patients with inhibitors to close care gaps and improve outcomes. Ther Adv Drug Saf 2011;2(05):213–225.

Sørensen B, Ingerslev J. Tailoring haemostatic treatment to patient requirements - an update on monitoring haemostatic response using thrombelastography. Haemophilia 2005;11(Supp 1):1–6.

Väرادی K, Négrier C, Berntorp E, et al. Monitoring the bioavailability of FEIBA with a thrombin generation assay. J ThrombHaemost 2003;1(11):2374–2380.

Wendyja J, Holme P, Hermans C, et al. Real world clinical management of patients with hemophilia and inhibitors: effectiveness and safety of aPCC in patients with >18 months’ follow-up in the FEIBA Global Outcome study (FEIBA GO). Blood 2019;134(S1):2418.

Ali TMCR, Wanek K, Cano V. Tolerability/safety of FEIBA reconstituted in regular or 50% reduced volume and faster infusion rates: rationale and study design in patients with hemophilia A or B with inhibitors. Haemophilia 2018;24(S1):119.

Berntorp E. Differential response to bypassing agents complicates treatment in patients with haemophilia and inhibitors. Haemophilia 2009;15(01):3–10.

Genentech Inc. Hemlibra (emicizumab-kxwh) injection for subcutaneous use [Prescribing Information]. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761083s000lbl.pdf. Published November 2017. Accessed January 2, 2020.

Mahlangu J, Oldenburg J, Paz-Priel I, et al. Emicizumab prophylaxis in patients who have hemophilia A without inhibitors. N Engl J Med 2018;379(09):811–822.

Callaghan MU, Sidonio R, Pipe SW. Novel therapeutics for hemophilia and other bleeding disorders. Blood 2018;132(01):23–30.

Oldenburg J, Mahlangu JW, Kim B, et al. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377(09):809–818.

Seaman CD, Ragni MV. Emicizumab use in major orthopedic surgery. Blood Adv 2019;3(11):1722–1724.

Santagostino E, Mancuso ME, Novembrino C, Solimeno LP, Tripodi A, Peviani F. Rescue factor VIII replacement to secure hemostasis in a patient with hemophilia A and inhibitors on emicizumab prophylaxis undergoing hip replacement. Haematologica 2019;104(08):e380–e382.

Zimowsk I, Batsui GM, Reding MT, et al. Maintaining perioperative hemostasis in patients with severe hemophilia A and inhibitors receiving emicizumab prophylaxis. Blood 2018;132:635.

Kruse-Jarres R, Callaghan MU, Croteau SE, et al. Surgical experience in two multicenter, open-label phase 3 studies of emicizumab in persons with hemophilia A with inhibitors (HAVEN 1 and HAVEN 2). Blood 2017;130:89.
Brophy DF, Martin EJ, Kuhn J. Use of global assays to monitor emicizumab prophylactic therapy in patients with haemophilia A with inhibitors. Haemophilia 2019;25(02):e121–e123

Dargaud Y, Lienhart A, Janbain M, Le Quellec S, Enjolras N, Négrier C. Use of thrombin generation assay to personalize treatment of breakthrough bleeds in a patient with hemophilia and inhibitors receiving prophylaxis with emicizumab. Haematologica 2018;103(04):e181–e183

Dargaud Y, Lienhart A, Négrier C. Prospective assessment of thrombin generation test for dose monitoring of bypassing therapy in hemophilia patients with inhibitors undergoing elective surgery. Blood 2010;116(25):5734–5737

van Veen JI, Gatt A, Bowyer AE, Cooper PC, Kitchen S, Makris M. The effect of tissue factor concentration on calibrated automated thrombography in the presence of inhibitor bypass agents. Int J Lab Hematol 2009;31(02):189–198

Luna-Záizar H, Beltrán-Miranda CP, Esparza-Flores MA, et al. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors. Haemophilia 2014;20(01):e7–e14

Turecek PL, Váradi K, Keil B, et al. Factor VIII inhibitor-bypassing agents act by inducing thrombin generation and can be monitored by a thrombin generation assay. Pathophysiology 2003;33(01):16–22

Jiménez-Yuste V, Klamroth R, Castaman G, et al. A single-arm, multicentre, open-label, phase III clinical trial to evaluate the safety and tolerability of prophylactic emicizumab in persons with haemophilia A (PwHA) with FVIII inhibitors (STASEY): interim analysis results. Res Pract Thromb Haemost 2019;3(51):116–117

Hartmann R, Feenstra T, Valentino L, Dockal M, Scheiffinger F. In vitro studies show synergistic effects of a procoagulant bispecific antibody and bypassing agents. J Thromb Haemost 2018;16:1580–1591

Oldenburg J, Levy GG. Emicizumab prophylaxis in hemophilia A with inhibitors. N Engl J Med 2017;377(22):2194–2195

Tiede A. Thromboembolic risks of non-factor replacement therapies in hemophilia. Hamostaseologie 2017;37(04):307–310

Dimichele D, Négrier C. A retrospective postlicensure survey of Oldenburg J, Levy GG. Emicizumab prophylaxis in hemophilia A with inhibitors: ef in patients with severe haemophilia A or B. Res Pract Thromb Haemost 2019;3(51):85–86

Groupo RA, Malan D, Kapocsi J, et al; Marzeptacog alfa (activated) Study Group Investigators. Phase 1, single-dose escalating study of marzeptacog alfa (activated), a recombinant factor VIIa variant, in patients with severe hemophilia. J Thromb Haemost 2018;16(10):1984–1993

Mahlangu J, Levy H, Khachchatryan H, et al. Phase 2/3 trial of subcutaneous engineered FVIIa marzeptacoga Lfa (activated) in hemophilia A or B with inhibitors: efficacy, safety and pharmacokinetics. Res Pract Thromb Haemost 2019;3(51):86–87

PR Newswire. HEMA Biologics, LLC announced today the acceptance by U.S. Food and Drug Administration of the submitted biologic license application for coagulation factor VIIa recombinant (epatcog beta activated). Available at: https://www.prnewswire.com/news-releases/HEMA-Biologics-LLC-announced-today-the-acceptance-by-us-food-and-drug-administration-of-the-submitted-biologic-license-application-for-coagulation-factor-vii-a-recombinant-epatcog-beta-activated-300387578.html. Published 2017. Accessed January 2, 2020

Hema Biologics. Pipeline. Available at: https://hembio.com/pipeLine/. Published 2019. Accessed January 2, 2020

George LA. Hemophilia gene therapy comes of age. Hematology (Am Soc Hematol Edu Program) 2017;2017(01):587–594

Yamaguti–Hayakawa GG, Ozelo MC. Gene therapy: paving new roads in the treatment of hemophilia. Semin Thromb Hemost 2019;45(07):743–750

UniQure. Gene therapy: hemophilia. Available at: http://www.uniQure.com/gene-therapy/hemophilia.php. Published 2019. Accessed January 2, 2020

Shapiro AD, Mitchell IS, Nasr S. The future of bypassing agents for hemophilia with inhibitors in the era of novel agents. J Thromb Haemost 2018;16(12):2362–2374

Susen S, Gruel Y, Godier A, et al. Management of bleeding and invasive procedures in haemophilia A patients with inhibitor treated with emicizumab (Hemlibra®): proposals from the French network on inherited bleeding disorders (MHÉMO), the French Reference Centre on Haemophilia, in collaboration with the French Working Group on Perioperative Haemostasis (GHP). Haemophilia 2019;25(05):731–737
Collins PW, Liesner R, Makris M, et al. Treatment of bleeding episodes in haemophilia A complicated by a factor VIII inhibitor in patients receiving Emicizumab. Interim guidance from UKHCDO Inhibitor Working Party and Executive Committee. Haemophilia 2018;24(03):344–347

Ljung R, Auerswald G, Benson G, et al. Inhibitors in haemophilia A and B: management of bleeds, inhibitor eradication and strategies for difficult-to-treat patients. Eur J Haematol 2019;102(02):111–122

Young G. How I treat children with haemophilia and inhibitors. Br J Haematol 2019;186(03):400–408

Sjamsoedin LJ, Heijnen L, Mauser-Bunschoten EP, et al. The effect of activated prothrombin-complex concentrate (FEIBA) on joint and muscle bleeding in patients with hemophilia A and antibodies to factor VIII. A double-blind clinical trial. N Engl J Med 1981;305(13):717–721

Hilgartner M, Aledort L, Andes A, Gill J; FEIBA Study Group. Efficacy and safety of vapor-heated anti-inhibitor coagulant complex in hemophilia patients. Transfusion 1990;30(07):626–630

Ehrlich HJ, Henzl MJ, Gomperts ED. Safety of factor VIII inhibitor bypass activity (FEIBA): 10-year compilation of thrombotic adverse events. Haemophilia 2002;8(02):83–90

Bui JD, Despotis GD, Trulock EP, Patterson GA, Goodnough LT. Fatal thrombosis after administration of activated prothrombin complex concentrates in a patient supported by extracorporeal membrane oxygenation who had received activated recombinant factor VII. J Thorac Cardiovasc Surg 2002;124(04):852–854

Rosenfeld SB, Watkinson KK, Thompson BH, Macfarlane DE, Lentz SR. Pulmonary embolism after sequential use of recombinant factor VIIa and activated prothrombin complex concentrate in a factor VIII inhibitor patient. Thromb Haemost 2002;87(05):925–926

Schneiderman J, Rubin E, Nugent DJ, Young G. Sequential therapy with activated prothrombin complex concentrates and recombinant FVIIa in patients with severe haemophilia and inhibitors: update of our previous experience. Haemophilia 2007;13(03):244–248

Eichler H, Angchaisukisri P, Kavakli K, et al. A randomized trial of safety, pharmacokinetics and pharmacodynamics of concizumab in people with hemophilia A. J Thromb Haemost 2018;16(11):2184–2195

Chowdary P, Lethagen S, Friedrich U, et al. Safety and pharmacokinetics of anti-TPF antibody (concizumab) in healthy volunteers and patients with hemophilia: a randomized first human dose trial. J Thromb Haemost 2015;13(05):743–754

Sehgal A, Barros S, Ivanciu L, et al. An RNAi therapeutic targeting antithrombin to rebalance the coagulation system and promote hemostasis in hemophilia. Nat Med 2015;21(05):492–497

Pasi KJ, Rangarajan S, Georgiev P, et al. Targeting of antithrombin in hemophilia A or B with RNAi therapy. N Engl J Med 2017;377(09):819–828